NCT03958708 is a Phase 1, PHASE2 clinical trial of Rifaximin 550 MG in Parkinson Disease, sponsored by Taipei Medical University Shuang Ho Hospital.

Who is sponsoring NCT03958708?

NCT03958708 is sponsored by Taipei Medical University Shuang Ho Hospital.

What drugs are being tested in NCT03958708?

Interventions in NCT03958708: Rifaximin 550 MG.

What condition does NCT03958708 study?

NCT03958708 studies Parkinson Disease, Inflammation.

Is NCT03958708 still recruiting?

NCT03958708 is currently status unknown. Last updated 22 May 2019.

Last reviewed 2019-05-22 · How we verify

NCT03958708

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modulation of Gut Microbiota by Rifaximin in PD Patients

Status unknown Phase 1, PHASE2 Last updated 22 May 2019

What this trial tests

Phase 1, PHASE2 trial testing Rifaximin 550 MG in Parkinson Disease in 20 participants. Status unknown.

Timeline

13 May 2019

Primary endpoint
12 May 2020

1 December 2020

Quick facts

Lead sponsor	Taipei Medical University Shuang Ho Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	13 May 2019
Primary completion	12 May 2020
Estimated completion	1 December 2020
Sites	1 location across Taiwan

Drugs / interventions tested

Rifaximin 550 MG — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →
Inflammation — all drugs for Inflammation →

Sponsor

Taipei Medical University Shuang Ho Hospital

Who can join

Adults 45 to 70, any sex, with Parkinson Disease or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purposes of this clinical trial are to test 1. Whether 1-week rifaximin treatment is able to restore the gut microbiota in a long-term manner in people with Parkinson's disease? 2. Whether the restoration of gut microbiota in people with Parkinson's disease is associated with the reduction of systemic inflammation and circulating exosomal α-synuclein?

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications.
Pajares M, I Rojo A, Manda G, Boscá L, et al · · 2020 · cited 531× · PMID 32674367 · DOI 10.3390/cells9071687
Biomarkers for Parkinson's Disease: How Good Are They?
Li T, Le W. · · 2020 · cited 105× · PMID 31646434 · DOI 10.1007/s12264-019-00433-1
Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications.
Giri PM, Banerjee A, Ghosal A, Layek B. · · 2024 · cited 66× · PMID 38612804 · DOI 10.3390/ijms25073995
Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson's Disease: Preclinical and Clinical Studies.
Hong CT, Chan L, Chen KY, Lee HH, et al · · 2022 · cited 35× · PMID 36359864 · DOI 10.3390/cells11213468
The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease.
Miao Y, Meng H. · · 2024 · cited 23× · PMID 38216911 · DOI 10.1186/s12964-023-01402-y
Targeting Microglia in Neuroinflammation: H3 Receptor Antagonists as a Novel Therapeutic Approach for Alzheimer's Disease, Parkinson's Disease, and Autism Spectrum Disorder.
Thomas SD, Abdalla S, Eissa N, Akour A, et al · · 2024 · cited 18× · PMID 39065682 · DOI 10.3390/ph17070831
"Janus-Faced" α-Synuclein: Role in Parkinson's Disease.
Ray B, Mahalakshmi AM, Tuladhar S, Bhat A, et al · · 2021 · cited 7× · PMID 34124057 · DOI 10.3389/fcell.2021.673395
Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497

Verify or expand the search:

Other trials of Rifaximin 550 MG

Trials testing the same drug.

NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
NCT05867550 — To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea · Phase 4 · completed
NCT03658993 — Rifaximin-treatment of Collagenous Colitis · Phase 3 · unknown
NCT03219528 — A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing · Phase 4 · completed

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Taipei Medical University Shuang Ho Hospital trials

Trials by the same sponsor.

NCT07380685 — On-Demand AI Support Via LINE-Based GPT Assistant to Improve Emotional Resilience and Reduce Burnout Among Clinical Nurs · NA · not yet recruiting
NCT07435714 — Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid · NA · not yet recruiting
NCT07230366 — Clinical Validation of AI-powered Smart Vehicle Assisted Gait Training in Neurodegenerative Disorders · NA · not yet recruiting
NCT07257393 — Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health · not yet recruiting
NCT07192042 — Investigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in Hospitalized Patients With Schizoph · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03958708 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University Shuang Ho Hospital
Last refreshed: 22 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03958708.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing